ENTRY       D11840                      Drug
NAME        Tilavonemab (USAN/INN)
FORMULA     C6480H9956N1720O2028S42
EXACT_MASS  145659.7071
MOL_WEIGHT  145749.4238
SEQUENCE    (Heavy chain)
            EVKVVESGGG LVQPGGSMKL SCVVSGFTFS NYWVNWVRQA PGKGLEWVAQ IRLKSDNYAT
            HYEESVKGRF TISRDDSKSS VYLQMNNLRA EDSGIYYCTN WEDYWGQGTT VTVSSASTKG
            PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
            SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP
            KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV
            LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ EEMTKNQVSL
            TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC
            SVMHEALHNH YTQKSLSLSL GK
            (Light chain)
            DIVLTQSPDS LAVSLGERAT ISCRASQSVS TSRYSYIHWY QQKPGQPPKL LIKYASNLES
            GVPSRFSGSG SGTDFTLNIH PLEPEDFATY YCHHSWEIPL TFGQGTKLEI KRTVAAPSVF
            IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
            STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
            (Disulfide bridge: H22-H98, H129-L218, H142-H198, H221-H'221, H224-H'224, H256-H316, H362-H420, H'22-H'98, H'129-L'218, H'142-H'198, H'256-H'316, H'362-H'420, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  TYPE      Peptide
EFFICACY    Dementia therapeutic agent, Anti-tau protein antibody
  TYPE      Monoclonal antibody
COMMENT     Treatment of Alzheimer's disease, supranuclear palsy and neurodegenerative disorders
TARGET      MAPT (TAU) [HSA:4137] [KO:K04380]
  PATHWAY   hsa04010(4137)  MAPK signaling pathway
            hsa05010(4137)  Alzheimer disease
            hsa05022(4137)  Pathways of neurodegeneration - multiple diseases
BRITE       Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                MAPT (TAU)
                 D11840  Tilavonemab (USAN/INN)
DBLINKS     CAS: 2096513-89-0
///
